DOCSLIB.ORG

289.Full.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
289.Full.Pdf AMERICAN ACADEMY OF PEDIATRICS COMMITTEE ON NUTRITION NUTRITIONAL MANAGEMENT IN HEREDITARY METABOLIC DISEASE T HIRTEEN YEARS AGO a dietary approach propriately given. Management begins with to the therapy of phenylketonuria was confirmation of the diagnosis by methods proposed,I.2 and data on the usefulness as more specific than those used in any screen- well as the very real limitations of this pro- ing program and continues with monitoring gram have accumulated in the intervening of the biochemical and biological response years. At the present time studies on the to dietary manipulations. This memoran- application of special diets for use in this dum discusses these and other general pm- disease, as well as for many other heredi- ciples. A handbook of treatment is not in- tary metabolic diseases, are in progress. As tended, and referral to the comprehensive wider use is made of procedures for detec- sources identified in Table I is recom- tion of hereditary metabolic disease in the mended for those requiring detailed infor- newborn,’ an increasingly larger number of mation about particular diseases. patients who may benefit from appropriate nutritional therapy will be identified very GENERAL PRINCIPLES early in life. For example, calculations The events depicted in Figure 1 underlie based on the current birth rate and appar- all types of hereditary metabolic disease. ent incidence of phenylketonuria indicate Mutation in the genorne, in one way or an- that as many as 4,000 infants with this dis- other, modifies a protein gene product. The order in the United States alone could re- gene product is called an apoenzyme when (luire dietary therapy in the next decade. the protein directs a specific biochemical There is, therefore, a need to evaluate the reaction. The association of a low-molecu- principles governing nutritional manage- lar weight compound or coenzyme ( 3 ) may ment of hereditary metabolic disease in also be required by the apoprotein to order to develop optimal treatment facili- achieve optimal catalytic rates; the corn- ties for use in conjunction with new detec- bined apoenzyme-coenzyme complex is tion methods. It seems anomalous that com- called the holoenzyme. Conversion of one paratively little has been done either to es- compound [substrate ( 1 )I into another tablish good treatment practices in heredi- [product ( 2 ) J, or transfer of unmodified tary metabolic disease or to mobilize scien- substrate from one side of the membrane to tific resources to ensure an optimistic out- the other, often against an electrochernical come for therapeutic endeavors, while so gradient, constithte the principal types of much emphasis has been placed on detec- “enzymatic” activity. tion. The inherited disorders of cellular me- Dietary treatment of hereditary metabolic tabolism and transport reflect alterations in disease is simple in theory; however, prac- structure, activity, or amount of enzyme. tical application may be unexpectedly Most of the diseases exhibit simple Men- difficult, or even hazardous, if not carefully delian inheritance and are the result of mu- supervised. It should be determined wheth- tation at a single genetic locus. Altered bio- er: (1) the untreated disease is in fact harm- chemical relations and associated clinical fill, ( 2 ) the treatment is useful in preventing consequences constitute the phenotype of or reversing the unfavorable progression of such a disease. Specific phenotypes can be the disease, (3) the therapy may be harmful described for almost all of these metabolic by interfering with growth or development, diseases. and ( 4 ) the program may be harmful to Ideal treatment would restore the normal others to whom it is inadvertently or map- genetic code as vell as subsequent tran- Prnu-nics, Vol. 40, No. 2, August 1967 289 Downloaded from www.aappublications.org/news by guest on September 28, 2021 290 NUTRITION IN METABOLIC DISEASE TABLE I TYPES OF HEREDITARY METABOLIC DISEASE APPARENTLY AMENABLE TO THERAPY Disorder Therapy Which Has Been Attempted Reference* Disorder8 of Amino Acid Meiabolism Essential Amino Acids Phenylketonuria (classical) Phenylalanine restriction 61, 62 See also Table III 63, 64, 65 Branch-chain ketoaminoaciduria (maple syrup urine disease) Restriction of leucine, isoleucine, and valine 39, 40 Hypervalinemia Valine restriction 66 Isovalericacidemiat (“sweaty-feet” syndrome) Protein restriction 67 Homocystinuria, with methioninemia Methionine restriction and cystine supplementation 68, 69, 69a Hi.stidinemia Early histidine restriction (?) 70 Hyperlysinemia Protein restriction 1.5 gm/kg/day (see also diseases of urea cycle) 71, 7, 73 Non-Essential Amino Acids Tyrosinemia hereditary form Tyrosine restriction and phenylalanine adjustment 53, 53a transient neonatal form Protein restriction 1-ascorbic acid 75 to 100 mg/day 45,46 Diseases of urea cycle Protein restriction for control of NH5 intoxication 74 hyperammonemia carbamyiphosphate synthetase deficiency Protein restriction for control of NH3 intoxication 75 ornithine transcarbamylase deficiency Protein restriction for control of NH3 intoxication 76 citrullinemia Protein restriction for control of NH3 intoxication 77 argininosuccirncaciduria Arginine supplementation in early infancy (?) protein restriction 78 The hyperglyeinemias acetolluric form Protein restriction (about 1 gm/kg/day) 79 bypo-oxaluric form Protein restriction? 80 Disorders of Amino Acid Transport Hartnup disease Nicotinic acid supplements; good general nutrition 81, 8 Tryptophanuria Nicotinic acid 83 Cystinuria Water; D-penicillamine 84, 85 with malabsorption or protein into1erance Variable 86,87 Methionine malabsorption Protein restriction 88 Tryptophan malabsorption (blue diaper syndrome) . Protein restriction 89 Miscellaneous Problems Vitamin B6 dependency syndromes Pyridoxine HC1 (10 mg/day or more) 7 cystathioninuria 55 vitamin B6 dependency and seizures 90, 90a familial xanthurenic-aciduria 91 familial pyridoxine responsive anemia 9 Folic acid diseases formimino transferase deficiency None known Histidine restriction? 93 FIGLU’uria, MD magaloblastic anemia and ataxia Folic acid 94 S Citation is either to a recent article, review, or “classical” paper, whichever provides the most useful informa- tion and bibliography concerning treatment. t L-valme metabolism per se is Ilot abnormal in this disorder affecting the degradation of the equivalent hydroxy acid. This may be a disorder of tryptophan pyrollase activity, and hence classified under essential amino acids. § Whether this constitutes disease separate from the three genotypes of cystinurias or is merely interesting associative phenomena is not clear. Downloaded from www.aappublications.org/news by guest on September 28, 2021 AMERICAN ACADEMY OF PEDIATRICS 291 Disorder Therapy Which Has Been Attempted Ref erence Disorders of Carbohydrate Metaboli3m Ilyperglucemia (Childhood Diabetes Mellitus) Dietary control Insulin 95 Hypoglucemia toxic (EDTA, salicylates, sulphonylu- reas, MOA inhibitors, etc.) Remove cause IV glucose 96 leucine sensitivity Protein restriction (steroids) 97, 98 idiopathic Steroids 101 ketotic Frequent feeding 1O deficient catecholamine# response Ephedrine 103, 104 Ilyperinsulinism Diazoxide Surgery 98 Glycogen storage diseases (Type 1-IX) Depends on type 106 Galactosemia (4 types: see text) Galactose restriction (need may be transient) (Preg- nancy-special need for Rx of mother) 41, 107 Fructose intolerance Restriction of fructose intake 108, 109 Glucose-galactose malabsorption Restriction of dietary carbohydrate 1 10, 111 Fructose-galactose intolerance Restriction of dietary carbohydrate (excluding glu- cose) 112 True congenital disaccharidase deficiency Long-term dietary restriction of offending disac- charide 113, 114, 115, 116, 117 Acquired disaccharidase deficiency Temporary restriction of offending disaccharides 118, 117 Disorders of Lipid Metabolism Familial hyperlipoproteinemia-5 types: Varies with type-includes: 119 hyperchylomicroenimia Medium chain triglyceride supplement increased fl-lipoprotein increased pre fi and fl-Lp Restriction of cholesterol increased pre fl-Lp Restriction of CHO combined hyper 3-Lp and hypochylomi- cronemia Polyunsaturated FA-supplement Abetalipoprotenemia Low fat diet 120 High density lipoprotein deficiency (Tangier disease) (None required usually) 121 Miscellaneous Gastrointestinal disorders gluten sensitive enteropathy Gluten restriction 122, 122a cystic fibrosis (intestinal component) Pancreatic enzyme replacement 123 trypsinogen deficiency Trypsinogen replacement 125 Disorders of mineral metabolism idiopathic hypercalcemia Avoid vitamin D excess 126 vitamin D dependency Vitamin D 50,000 units/day 127 renal phosphorus transport 10 to 20 gm neutral phosphase salt solutions (+ vitamin D in some cases) 127 Wilson’s disease D-Pencillamine 128 Disorders of pyrimidine metabolism familial hyperuricemia with finger chew- ing and MR Prohenecid, Alkalinization 129 oroticaciduria Uridine p.o. 150 mg every 4 to 6 hours 130, 5 This abnormality probably reflects aII exaggeration of a normal mechanism reducing hepatic glucose produc- tion rather than a genetically controlled metabolic abnormality.99100 # There is no evidence that the abnormality in adrenalin production in certain patients results from an hereditary enzymatic defect. Rather, it probably results from exhaustion of tile chromaffin system.1#{176}’ Downloaded from www.aappublications.org/news by guest on September 28, 2021 292 NUTRITION IN METABOLIC DISEASE scription
Load more

Recommended publications
  • Effect of Propionic Acid on Fatty Acid Oxidation and U Reagenesis
    Pediat. Res. 10: 683- 686 (1976) Fatty degeneration propionic acid hyperammonemia propionic acidemia liver ureagenesls Effect of Propionic Acid on Fatty Acid Oxidation and U reagenesis ALLEN M. GLASGOW(23) AND H. PET ER C HASE UniversilY of Colorado Medical Celller, B. F. SlOlillsky LaboralOries , Denver, Colorado, USA Extract phosphate-buffered salin e, harvested with a brief treatment wi th tryps in- EDTA, washed twice with ph os ph ate-buffered saline, and Propionic acid significantly inhibited "CO z production from then suspended in ph os ph ate-buffe red saline (145 m M N a, 4.15 [I-"ejpalmitate at a concentration of 10 11 M in control fibroblasts m M K, 140 m M c/, 9.36 m M PO" pH 7.4) . I n mos t cases the cells and 100 11M in methyl malonic fibroblasts. This inhibition was we re incubated in 3 ml phosph ate-bu ffered sa lin e cont aining 0.5 similar to that produced by 4-pentenoic acid. Methylmalonic acid I1Ci ll-I4Cj palm it ate (19), final concentration approximately 3 11M also inhibited ' 'C0 2 production from [V 'ejpalmitate, but only at a added in 10 II I hexane. Increasing the amount of hexane to 100 II I concentration of I mM in control cells and 5 mM in methyl malonic did not impair palmit ate ox id ation. In two experiments (Fig. 3) the cells. fibroblasts were in cub ated in 3 ml calcium-free Krebs-Ringer Propionic acid (5 mM) also inhibited ureagenesis in rat liver phosphate buffer (2) co nt ain in g 5 g/ 100 ml essent iall y fatty ac id slices when ammonia was the substrate but not with aspartate and free bovine se rum albumin (20), I mM pa lm itate, and the same citrulline as substrates.
    [Show full text]
  • Inherited Metabolic Disease
    Inherited metabolic disease Dr Neil W Hopper SRH Areas for discussion • Introduction to IEMs • Presentation • Initial treatment and investigation of IEMs • Hypoglycaemia • Hyperammonaemia • Other presentations • Management of intercurrent illness • Chronic management Inherited Metabolic Diseases • Result from a block to an essential pathway in the body's metabolism. • Huge number of conditions • All rare – very rare (except for one – 1:500) • Presentation can be non-specific so index of suspicion important • Mostly AR inheritance – ask about consanguinity Incidence (W. Midlands) • Amino acid disorders (excluding phenylketonuria) — 18.7 per 100,000 • Phenylketonuria — 8.1 per 100,000 • Organic acidemias — 12.6 per 100,000 • Urea cycle diseases — 4.5 per 100,000 • Glycogen storage diseases — 6.8 per 100,000 • Lysosomal storage diseases — 19.3 per 100,000 • Peroxisomal disorders — 7.4 per 100,000 • Mitochondrial diseases — 20.3 per 100,000 Pathophysiological classification • Disorders that result in toxic accumulation – Disorders of protein metabolism (eg, amino acidopathies, organic acidopathies, urea cycle defects) – Disorders of carbohydrate intolerance – Lysosomal storage disorders • Disorders of energy production, utilization – Fatty acid oxidation defects – Disorders of carbohydrate utilization, production (ie, glycogen storage disorders, disorders of gluconeogenesis and glycogenolysis) – Mitochondrial disorders – Peroxisomal disorders IMD presentations • ? IMD presentations • Screening – MCAD, PKU • Progressive unexplained neonatal
    [Show full text]
  • Inherited Metabolic Disorders)
    1 โรคพันธุกรรมเมตาบอลิก (inherited metabolic disorders) บทนํา โรคพันธุกรรมเมตาบอลิคนั้น มีผู้ประเมินไว้ว่ามีหลายร้อยโรคด้วยกัน และเป็นที่ยอมรับว่า อุบัติการของโรคกลุ่มนี้มักจะน้อยกว่าความเป็นจริง เนื่องจากการวินิจฉัยโรคทําได้ด้วยความ ยากลําบาก แพทย์ทั่วไปมักรู้จักค่อนข้างน้อย หรือให้การวินิจฉัยไม่ถูกต้อง ด้วยเหตุผลหลาย ประการ 1). การวินิจฉัยทําได้ค่อนข้างยาก เนื่องจากแต่ละโรคพบได้น้อยคือ จัดเป็น rare disease ทําให้แพทย์ไม่ค่อยนึกถึงเมื่อพบผู้ป่วย จนอาการค่อนข้างมาก หรือเมื่อได้แยกโรคที่พบได้บ่อย ออกไปแล้ว 2). การตรวจทางห้องปฎิบัติการโดยเฉพาะการตรวจเลือดและปัสสาวะเบื้องต้น มักไม่ ค่อยบอกโรคชัดเจน ยกเว้นส่งตรวจพิเศษบางอย่างเช่นการวิเคราะห์ plasma amino acid หรือ urine organic acid 3). ในทารกแรกเกิดซึ่งมีโอกาสพบโรคกลุ่มนี้ได้บ่อย มักจะมีการตอบสนองต่อ severe overwhelming illness อย่างมีขีดจํากัด หรือแสดงอาการอย่าง nonspecific เช่น poor feeding,lethargy เป็นต้น 4).กุมารแพทย์คิดถึงโรคกลุ่มนี้ในบางภาวะเท่านั้นเช่นภาวะปัญญาอ่อน หรือชักที่คุมได้ยากและมองข้ามอาการแสดงบางอย่างที่อาจเป็นเงื่อนงําสําคัญในการวินิจฉัยโรค โรคพันธุกรรมเมตาบอลิก ที่เรียกว่า inherited metabolic disorders หรือ inborn errors of metabolism (IBEM) เป็นโรคพันธุกรรมกลุ่มหนึ่งที่เกิดจากความผิดปกติของยีนเดี่ยว ที่มีความ ผิดปกติของการเรียงลําดับของเบสหรือสายDNA ก่อให้เกิดความผิดปกติของ enzymes, receptors, transport proteins, structural proteins, หรือส่วนประกอบอื่นของเซลล์แล้วส่งผลให้ เกิดความผิดปกติของขบวนการย่อยสลาย (catabolism) หรือขบวนการสังเคราะห์ (anabolism) สารอาหาร การเปลี่ยนแปลงที่ระดับ DNA ของโรคกลุ่มนี้อาจเกิดจากการกลายพันธุ์ของยีนที่สร้าง enzyme หรือยีนที่สร้างสารควบคุมหรือส่งเสริมการทํางานของ
    [Show full text]
  • Metabolomic Analysis Reveals That the Drosophila Gene Lysine Influences Diverse Aspects of Metabolism
    Genetics: Early Online, published on October 6, 2017 as 10.1534/genetics.117.300201 Metabolomic analysis reveals that the Drosophila gene lysine influences diverse aspects of metabolism Samantha L. St. Clair*‡, Hongde Li*‡, Usman Ashraf†, Jonathan A. Karty†, and Jason M. *§ Tennessen * Department of Biology, Indiana University, Bloomington, IN 47405, USA † Department of Chemistry, Indiana University, Bloomington, IN, 47405, USA. ‡ These authors contributed equally to this work. § Correspondence: [email protected] Keywords: Drosophila, metabolomics, lysine, LKRSDH, familial hyperlysinemia 1 Copyright 2017. ABSTRACT The fruit fly Drosophila melanogaster has emerged as a powerful model for investigating the molecular mechanisms that regulate animal metabolism. A major limitation of these studies, however, is that many metabolic assays are tedious, dedicated to analyzing a single molecule, and rely on indirect measurements. As a result, Drosophila geneticists commonly use candidate gene approaches, which, while important, bias studies towards known metabolic regulators. In an effort to expand the scope of Drosophila metabolic studies, we used the classic mutant lysine (lys) to demonstrate how a modern metabolomics approach can be used to conduct forward genetic studies. Using an inexpensive and well-established gas chromatography-mass spectrometry (GC-MS)-based method, we genetically mapped and molecularly characterized lys by using free lysine levels as a phenotypic readout. Our efforts revealed that lys encodes the Drosophila homolog of Lysine Ketoglutarate Reductase/Saccharopine Dehydrogenase (LKRSDH), which is required for the enzymatic degradation of lysine. Furthermore, this approach also allowed us to simultaneously survey a large swath of intermediate metabolism, thus demonstrating that Drosophila lysine catabolism is complex and capable of influencing seemingly unrelated metabolic pathways.
    [Show full text]
  • Amino Acid Disorders
    471 Review Article on Inborn Errors of Metabolism Page 1 of 10 Amino acid disorders Ermal Aliu1, Shibani Kanungo2, Georgianne L. Arnold1 1Children’s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; 2Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, MI, USA Contributions: (I) Conception and design: S Kanungo, GL Arnold; (II) Administrative support: S Kanungo; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: E Aliu, GL Arnold; (V) Data analysis and interpretation: None; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Georgianne L. Arnold, MD. UPMC Children’s Hospital of Pittsburgh, 4401 Penn Avenue, Suite 1200, Pittsburgh, PA 15224, USA. Email: [email protected]. Abstract: Amino acids serve as key building blocks and as an energy source for cell repair, survival, regeneration and growth. Each amino acid has an amino group, a carboxylic acid, and a unique carbon structure. Human utilize 21 different amino acids; most of these can be synthesized endogenously, but 9 are “essential” in that they must be ingested in the diet. In addition to their role as building blocks of protein, amino acids are key energy source (ketogenic, glucogenic or both), are building blocks of Kreb’s (aka TCA) cycle intermediates and other metabolites, and recycled as needed. A metabolic defect in the metabolism of tyrosine (homogentisic acid oxidase deficiency) historically defined Archibald Garrod as key architect in linking biochemistry, genetics and medicine and creation of the term ‘Inborn Error of Metabolism’ (IEM). The key concept of a single gene defect leading to a single enzyme dysfunction, leading to “intoxication” with a precursor in the metabolic pathway was vital to linking genetics and metabolic disorders and developing screening and treatment approaches as described in other chapters in this issue.
    [Show full text]
  • Formula Name Category Description Qualifying
    Memorandum #17-079 TO: WIC Regional Directors WIC Local Agency Directors FROM: Amanda Hovis, Director Nutrition Education/Clinic Services Unit Nutrition Services Section DATE: August 4, 2017 SUBJECT: Revised Formula Approval Resources Posted The formula approval resources have been revised to reflect the recent clinic formula table changes and will be posted to the DSHS WIC website. You will be able view them at the following link under “Formula Approval Resources” once they are posted. http://www.dshs.texas.gov/wichd/nut/foods-nut.shtm The following documents have been revised for July, 2017. Presently, they are attached to this memo as PDF files. 1. Texas WIC Formulary 2. Formula Code List 3. Texas WIC Formula Maximum Quantity Table 4. Nutrition Assessment Requirements Guide If you have questions or require additional information, contact Pat Koym, Formula Specialist, at [email protected] or 512-341-4578. This institution is an equal opportunity provider TEXAS WIC FORMULARY AND MEDICAL REASONS FOR ISSUANCE JULY 2017 Formula Category Description Qualifying Conditions Staff Instructions - May issue for 1 cert Manufacturer Name period unless otherwise indicated Alfamino Infant Elemental 20 cal/oz when mixed 1 scoop to 1 oz 1) Malabsorption syndrome Formula history required. Nestle water; hypoallergenic amino acid 2) GI impairment When requested for food allergy - a failed trial of a protein based elemental. 43% of fat is MCT 3) GER/GERD hydrolysate (Extensive HA, Nutramigen, Alimentum, or oil; Similar to Elecare DHA/ARA, 4) Food allergies (cow's milk, soy or Pregestimil) is recommended before issuing unless medically Neocate DHA/ARA and PurAmino.
    [Show full text]
  • Table S1. Disease Classification and Disease-Reaction Association
    Table S1. Disease classification and disease-reaction association Disorder class Associated reactions cross Disease Ref[Goh check et al.
    [Show full text]
  • Clinical and Molecular Characterization of Three Patients
    Mahjoub et al. BMC Medical Genetics (2019) 20:167 https://doi.org/10.1186/s12881-019-0893-9 CASE REPORT Open Access Clinical and molecular characterization of three patients with Hepatocerebral form of mitochondrial DNA depletion syndrome: a case series Ghazale Mahjoub1, Parham Habibzadeh1,2, Hassan Dastsooz1,3, Malihe Mirzaei1, Arghavan Kavosi1, Laila Jamali1, Haniyeh Javanmardi2, Pegah Katibeh4, Mohammad Ali Faghihi1,5 and Seyed Alireza Dastgheib6* Abstract Background: Mitochondrial DNA depletion syndromes (MDS) are clinically and phenotypically heterogeneous disorders resulting from nuclear gene mutations. The affected individuals represent a notable reduction in mitochondrial DNA (mtDNA) content, which leads to malfunction of the components of the respiratory chain. MDS is classified according to the type of affected tissue; the most common type is hepatocerebral form, which is attributed to mutations in nuclear genes such as DGUOK and MPV17. These two genes encode mitochondrial proteins and play major roles in mtDNA synthesis. Case presentation: In this investigation patients in three families affected by hepatocerebral form of MDS who were initially diagnosed with tyrosinemia underwent full clinical evaluation. Furthermore, the causative mutations were identified using next generation sequencing and were subsequently validated using sanger sequencing. The effect of the mutations on the gene expression was also studied using real-time PCR. A pathogenic heterozygous frameshift deletion mutation in DGUOK gene was identified in parents of two affected patients (c.706–707 + 2 del: p.k236 fs) presenting with jaundice, impaired fetal growth, low-birth weight, and failure to thrive who died at the age of 3 and 6 months in family I. Moreover, a novel splice site mutation in MPV17 gene (c.461 + 1G > C) was identified in a patient with jaundice, muscle weakness, and failure to thrive who died due to hepatic failure at the age of 4 months.
    [Show full text]
  • Cystathioninuria from Pyridoxine Deficiency Complicating Treatment of Hypercalcaemia in a Cretin
    Arch Dis Child: first published as 10.1136/adc.41.217.273 on 1 June 1966. Downloaded from Arch. Dis. Childh., 1966, 41, 273. Cystathioninuria from Pyridoxine Deficiency Complicating Treatment of Hypercalcaemia in a Cretin PAUL FOURMAN, JEAN W. SUMMERSCALES, and D. M. MORGAN From the Departments of Chemical Pathology and Paediatrics, Leeds General Infirmary Rats with vitamin B6 deficiency excrete cysta- deficiency may continue to make cystathionine but thionine in the urine (Hope, 1957). Cystathionine they fail to split it. is an amino acid in the pathway of synthesis of Pyridoxal phosphate is a co-enzyme for many cysteine from methionine (Fig. 1). A methyl group other enzymes that are important in metabolism is removed from methionine to produce homocyst- (Holtz and Palm, 1964), including certain trans- eine, which condenses with serine to yield cysta- aminases and decarboxylases. Several of the thionine. This condensation is catalysed by a enzymes concerned in tryptophan metabolism transulphurase enzyme requiring pyridoxal phos- require pyridoxal phosphate. The net effect of phate as a co-enzyme. Finally, cystathionine splits vitamin B6 deficiency on tryptophan metabolism is to yield cysteine and homoserine. This reaction is usually to increase the excretion of xanthurenic acid, catalysed by cystathionase and also requires particularly after the addition ofa dose of tryptophan pyridoxal phosphate (White, Handler, and Smith, to the diet, but the precise reason for the increased 1964). Pyridoxal and its phosphate are forms of xanthurenic acid excretion is not clear (Greenberg, vitamin B6, the others being pyridoxamine and its Bohr, McGrath, and Rinehart, 1949; Holtz and copyright. phosphate, and pyridoxine.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0134109 A1 Gaitanaris Et Al
    US 2006O134109A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0134109 A1 Gaitanaris et al. (43) Pub. Date: Jun. 22, 2006 (54) GPROTEIN COUPLED RECEPTORS AND in-part of application No. 60/461.329, filed on Apr. 9. USES THEREOF 2003. (75) Inventors: George A. Gaitanaris, Seattle, WA Publication Classification (US); John E. Bergmann, Mercer Island, WA (US); Alexander Gragerov, (51) Int. Cl. Seattle, WA (US); John Hohmann, La CI2O I/68 (2006.01) Conner, WA (US); Fusheng Li, Seattle, C7H 2L/04 (2006.01) WA (US); Linda Madisen, Seattle, WA (US); Kellie L. McIlwain, Renton, WA CI2P 2/06 (2006.01) (US); Maria N. Pavlova, Seattle, WA A 6LX 39/395 (2006.01) (US); Demitri Vassilatis, Seattle, WA C07K I4/705 (2006.01) (US); Hongkui Zeng, Shoreline, WA (52) U.S. Cl. ......................... 424/143.1: 435/6: 435/69.1; 435/320.1; 435/325; 530/350; (US) 536/23.5 Correspondence Address: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC (57) ABSTRACT 701 FIFTHAVE SUTE 63OO The present invention provides GPCR polypeptides and SEATTLE, WA 98104-7092 (US) polynucleotides, recombinant materials, and transgenic (73) Assignee: Nura Inc., Seattle, WA (US) mice, as well as methods for their production. The polypep tides and polynucleotides are useful, for example, in meth (21) Appl. No.: 10/527,265 ods of diagnosis and treatment of diseases and disorders. The invention also provides methods for identifying com (22) PCT Fed: Sep. 9, 2003 pounds (e.g., agonists or antagonists) using the GPCR polypeptides and polynucleotides of the invention, and for (86) PCT No.: PCT/USO3/28226 treating conditions associated with GPCR dysfunction with the GPCR polypeptides, polynucleotides, or identified com Related U.S.
    [Show full text]
  • Cystathionline + H20 -- Cysteine + A-Ketobutyrate + NH3
    VOL. 55, 1966 BIOCHEMISTRY: FINKELSTEIN ET AL. 865 17 Georgiev, G. P., 0. P. Samarina, M. I. Lerman, M. N. Smirnov, and A. N. Severtzov, Nature, 200, 1291 (1963). 8Greenman, D. L., W. D. Wicks, and F. T. Kenney, J. Biol. Chem., 240, 4420 (1965). 19 Paigen, K., J. Theor. Bwl., 3, 268 (1962). 20 Zubay, G., and M; H. F. Wilkins, J. Mol. Biol., 4, 444 (1962). 21 Zubay, G., in The Nucleohistones, ed. J. Bonner and P. Ts'o (San Francisco: Holden-Day, 1964), p. 95. 22Frenster, J. H., Nature, 206, 1269 (1965). DEFICIENCIES OF CYSTATHIONASE AND HOMOSERINE DEHYDRA TASE ACTIVITIES IN CYSTA THIONINURIA BY JAMES D. FINKELSTEIN, S. HARVEY MUDD, FILADELFO IRREVERRE, AND LEONARD LASTER VETERANS ADMINISTRATION HOSPITAL, WASHINGTON, D.C., NATIONAL INSTITUTE OF MENTAL HEALTH AND NATIONAL INSTITUTE OF ARTHRITIS AND METABOLIC DISEASES, NATIONAL INSTITUTES OF HEALTH, BETHESDA, MARYLAND Communicated by Seymour S. Kety, February 16, 1966 Congenital cystathioninuria is a familial disease first reported in 1958.1 Too few patients with this condition have been studied to allow definition of the clinical syndrome, but it may include various congenital defects and mental retardation or aberration.'-3 Harris et al.,' and subsequently Brenton et al.,4 demonstrated ab- normally high concentrations of cystathionine in tissue extracts from a cystathio- ninuric patient. Cystathionine was detected also in the serum of a patient reported by Frimpter et al.2 The presence of increased tissue cystathionine content led Harris et al. to advance the hypothesis that this syndrome resulted from a deficiency of the enzyme cystathionase,3 which normally cleaves cystathionine (reaction 1):1 Cystathionline + H20 -- cysteine + a-ketobutyrate + NH3.
    [Show full text]
  • Catabolism of the Carbon Skeletons of Amino Acids
    Bio. 2. ASPU. Lectu.3. Prof. Dr. F. ALQuobaili Catabolism of the Carbon Skeletons of Amino Acids • Biomedical Importance ‐ The metabolic diseases or "inborn errors of metabolism" associated with conversion of the carbon skeletons of the common L ‐‐amino acids to amphibolic intermediates can result in irreversible brain damage and .(ﺍﻟﻭﻓﺎﺓ) early mortality ‐ Prenatal or early postnatal detection and timely initiation of treatment thus are essential. Almost all states conduct screening tests for up to as many as 30 metabolic diseases. ‐ The best screening tests use tandem mass spectrometry to detect, in a few drops of neonate blood, catabolites suggestive of a metabolic defect. ‐ Treatment consists primarily of feeding diets low in the amino acids whose catabolism is impaired. • Transamination Typically Initiates Amino Acid Catabolism Removal of ‐amino nitrogen by transamination is the first catabolic reaction of amino acids except for proline, hydroxyproline, threonine, and lysine. The hydrocarbon skeleton that remains is then degraded to amphibolic intermediates. • Asparagine, Aspartate, Glutamine, and Glutamate All four carbons of asparagine and aspartate form oxaloacetate. Analogous reactions convert glutamine and glutamate to ‐ ketoglutarate. No metabolic defects are associated with the catabolism of these four amino acids. • Proline The catabolism of proline takes place in mitochodria. Since proline does not participate in transamination, the nitrogen of this imino acid is retained throughout its oxidation to 1‐ pyrolline‐5‐carboxylate, ring opening to glutamate‐‐ semialdehyde, and oxidation to glutamate, and is only removed during transamination of glutamate to ‐ketoglutarate. There are two metabolic disorders of proline catabolism. Both types are inherited as autosomal recessive traits, and are consistent with a normal adult life.
    [Show full text]